Analysis Replimune Finally Breaks Through: A $450,000 Melanoma Therapy Enters a Crowded Field
The biotech playbook often reads like a study in delayed gratification, and Replimune Group just authored its own chapter. After absorbing two Complete Response Letters and a skeptical staff review...